Argenica Therapeutics: Funding, Investors & Team (Sep 2026)
To enhance outcomes for stroke patients, Argenica is creating and attempting to commercialise a "best in class" neuroprotective cationic arginine-rich peptide treatment. Stroke is the greatest cause of mortality and disability worldwide, and its treatment and aftercare have high financial expenses. With existing therapies, 20% of patients pass away and 50% develop permanent disabilities. Additionally, the prevalence of stroke is rising due to the ongoing epidemics of cardiovascular disease, diabetes, and obesity as well as an ageing population. The only available treatments at this time are mechanical thrombectomy and tPA (alteplase) thrombolysis for clearing blood clots. Despite extensive study, there are no commercially available medications that can shield the brain from harm after a stroke.
Argenica Therapeutics has raised $840k across 1 funding round on record, the most recent an undisclosed round of $840k announced in Jan 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Argenica Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2023.
Argenica Therapeutics Funding Rounds
Argenica Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Argenica Therapeutics Funding Compared to Other Biotechnology Startups
Argenica Therapeutics' latest round of $840k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Argenica Therapeutics in Biotechnology and Nedlands
Companies Similar to Argenica Therapeutics
AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes…
The objective of Fluent is to seamlessly integrate humans with AI, improving interaction and communication…
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's…
Microba Life Sciences Ltd. provides consumers, doctors, and researchers with gut microbiome testing services…
Algenie was founded on a simple realization: algae has the potential to save the earth, but only if it is…
Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver…
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing…
Cauldron Ferm is a technique that speeds up the production of precision fermented prototypes to commercial…
HydGene Renewables is developing a biotechnology platform that produces on-site green hydrogen from waste…
Swan Genomics is focused on commercialising an innovative new approach to DNA sequencing to deliver more…
Argenica Therapeutics Funding FAQs
What does Argenica Therapeutics do?
To enhance outcomes for stroke patients, Argenica is creating and attempting to commercialise a "best in class" neuroprotective cationic arginine-rich peptide treatment. Stroke is the greatest cause of mortality and disability worldwide, and its treatment and aftercare have high financial expenses. With existing therapies, 20% of patients pass away and 50% develop permanent disabilities. Additionally, the prevalence of stroke is rising due to the ongoing epidemics of cardiovascular disease, diabetes, and obesity as well as an ageing population. The only available treatments at this time are mechanical thrombectomy and tPA (alteplase) thrombolysis for clearing blood clots. Despite extensive study, there are no commercially available medications that can shield the brain from harm after a stroke.
How much funding has Argenica Therapeutics raised?
Argenica Therapeutics has raised $840k across 1 round on record. The most recent is an undisclosed round of $840k announced in Jan 2023.
When did Argenica Therapeutics last raise funding?
Argenica Therapeutics' most recent funding round on record is an undisclosed round of $840k, announced in Jan 2023.
Who is the CEO of Argenica Therapeutics?
Dr Liz Dallimore is listed as CEO at Argenica Therapeutics.
Where is Argenica Therapeutics headquartered?
Argenica Therapeutics is based in Nedlands, Western Australia, Australia.
How many employees does Argenica Therapeutics have?
Argenica Therapeutics is in the 1-10 employee band.
How does Argenica Therapeutics' funding compare to other Biotechnology startups?
Argenica Therapeutics' latest round of $840k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Argenica Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Argenica Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.